Quantcast

Industry news that matters to you.  Learn more

USC Studies Nitric Oxide’s Link to Asthma

Children with elevated levels of exhaled nitric oxide (FeNO) are at increased risk for developing asthma, particularly among children without a parental history of the disease, a study by researchers at the Keck School of Medicine of USC has found. The study is published in the European Respiratory Journal.

New UC Davis Study Finds Early Alzheimer’s Identification Method

Abnormal brain images combined with examination of the composition of the fluid that surrounds the spine may offer the earliest signs identifying healthy older adults at risk of developing Alzheimer’s disease, well before cognitive problems emerge, a study by researchers at UC Davis has found.

UC San Diego Brain Tumor Treatment Program Launches Personalized Biomarker Clinical Study

The Brain Tumor Unit at the Moores UCSD Cancer Center at the University of California, San Diego in La Jolla, is launching a clinical trial that will examine the use of biomarkers to advance the treatment of malignant gliomas, brain tumors that start in the brain or spinal cord tissue. Annually, about 17,000 Americans are diagnosed with gliomas, which are difficult to treat and often fatal.

Clarient Receives Patents for Taxane Biomarker

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company’s TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy. In addition, the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent on the TLE3 biomarker. Other patents for the TLE3 biomarker are pending in the U.S., Canada, Japan, China, India and elsewhere in Europe.

New Molecular Imaging Biomarker Efficiently Demonstrates Malignant Prostate Tumors

Thomas Jefferson University in Philadelphia, PA and NuView Life Sciences of Park City, UT have entered into an exclusive licensing agreement for advancing the development of a new molecular imaging (MI) compound which identifies genomic expressions linked to prostate cancer (PC).